Company news

Ardelyx, Inc. news in 2026

Ardelyx, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update

November 3, 2026

Ardelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial of IBSRELA® (tenapanor) in Adults with Chronic Idiopathic Constipation

November 3, 2026

Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders

October 23, 2026

Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026

October 20, 2026

Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C

October 12, 2026

Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026

October 5, 2026

Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards

September 30, 2026

Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)

August 6, 2026

Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026

Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026

July 23, 2026

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026

May 19, 2026

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings

May 7, 2026

Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update

April 30, 2026

Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings

April 27, 2026

Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

April 23, 2026

Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

April 20, 2026

Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026

April 16, 2026

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

March 31, 2026

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

March 11, 2026

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

March 8, 2026

Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

February 23, 2026

Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 19, 2026

Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

February 4, 2026

Ardelyx Receives New Patent for Tenapanor

February 3, 2026

First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

January 28, 2026

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

January 8, 2026

Calls in 2026

Decks in 2026